Johnson & Johnson (JNJ) Earnings

<p>David Toung says the FDA panel is not expected to approve the resumption of JNJ's vaccine this week. For the company, the vaccine issue may not be a material concern to the company's earnings and revenue Medical devices are expected to show robust growth due to elective procedures and consumer health products are expected to show improving sales. </p>